Clinical trial
Extension Study of the Efficacy and Safety of Deferasirox Treatment in…
NCT00171301 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00171301 |
|---|---|
| Title | Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) |
| Official title | 1-year Extension to CICL670A2402 an Open-label, Multi-center Trial of the Efficacy and Safety of Long-term Treatment With Deferasirox (10 to 20 mg/kg/Day) in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2- Year Duration) |
| Acronym | ESCALATOR |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Beta-thalassemia Major, Hemosiderosis, Iron Overload, Rare Anemia |
| Intervention type | Drug |
| Interventions | Deferasirox |
| Enrollment | 233 |
| Start date | Jun 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Sep 15, 2005 |
| Last update posted | Aug 31, 2011 |
| Countries | Egypt, Lebanon, Oman, Saudi Arabia, Syria |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: